SCHEMBL14829072

SCHEMBL14829072

Clc1cnc2nc(Cl)c(Cl)nc2c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.39
HSD17B10 Q99714 1/20 0.39
TDP1 Q9NUW8 1/20 0.37
GUSB P08236 3/20 0.33
AURKA O14965 1/20 0.33
KIF11 P52732 1/20 0.33
NOS1 P29475 2/20 0.32
NR4A2 P43354 1/20 0.32
DYRK1A Q13627 1/20 0.32
POLB P06746 1/20 0.32
HPGD P15428 1/20 0.32
LMNA P02545 1/20 0.31
CYP2C9 P11712 1/20 0.31
TSHR P16473 1/20 0.31
APEX1 P27695 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
HRH4 Q9H3N8 3/20 0.31
PDGFRB P09619 1/20 0.31
PDGFRA P16234 1/20 0.31
PLAU P00749 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14828940 0.79 HTT (0.33) HTTHSD17B10
SCHEMBL14828799 0.78 CYP1A2 (0.39) HTTTDP1AURKANOS1SMN1; SMN2
SCHEMBL4681658 0.78 HTT (0.49) HTTTDP1AURKADYRK1ASMN1; SMN2
SCHEMBL14829134 0.78 GUSB (0.38) HTTHSD17B10GUSBAURKAKIF11
SCHEMBL14828809 0.78 TDP1 (0.34) TDP1
SCHEMBL28515716 0.75 HRH4 (0.35) HRH4
SCHEMBL14828967 0.74 ALDH1A1 (0.41) HTTHSD17B10TDP1POLBHPGD
SCHEMBL14828828 0.73 KDM4E (0.39) HTTHSD17B10POLBLMNATSHR
SCHEMBL14828829 0.72 HRH4 (0.56) SMN1; SMN2HRH4
SCHEMBL29070960 0.72 ALDH1A1 (0.42) HTTHSD17B10NR4A2DYRK1AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3461825-B1 NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES C&C RES LAB (KR) 2023-06-07 EP disclosed
US-20210198259-A1 HETEROCYCLIC DERIVATIVES AND USE THEREOF C&C RESEARCH LABORATORIES (KR) 2021-07-01 US disclosed
EP-3807282-A1 HETEROCYCLIC DERIVATIVES AND USE THEREOF C&C Research Laboratories (KR) 2021-04-21 EP disclosed
CN-112204032-A Heterocyclic derivatives and use thereof C&C新药研究所 2021-01-08 CN disclosed
EP-3461825-A1 NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES C&C Research Laboratories (KR) 2019-04-03 EP disclosed
EP-2760865-B1 NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES C&C RES LAB (KR) 2018-07-11 EP disclosed
US-9586959-B2 Substituted tricyclic heterocycles as histamine 4 receptor inhibitors C&C RESEARCH LABORATORIES (KR) 2017-03-07 US disclosed
US-20140315888-A1 NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES C&C RESEARCH LABORATORIES (KR) 2014-10-23 US disclosed
EP-2760865-A2 NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES C&C Research Laboratories (KR) 2014-08-06 EP disclosed
WO-2013048214-A2 NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES C&C RESEARCH LABORATORIES (KR) 2013-04-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210198259-A1 HETEROCYCLIC DERIVATIVES AND USE THEREOF HRH4, HRH2, HRH1 HTT 532/4885HSD17B10 4154/4885TDP1 4024/4885
US-20140315888-A1 NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES HRH4, HRH2, HRH1 HTT 740/4885HSD17B10 4521/4885TDP1 4404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.